# An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL®

> **NCT06145217** · PHASE1 · COMPLETED · sponsor: **Xspray Pharma AB** · enrollment: 18 (actual)

## Conditions studied

- Drug-drug Interaction Study

## Interventions

- **DRUG:** SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets in combination with Omeprazole Delayed-Release Capsules USP, 40 mg

## Key facts

- **NCT ID:** NCT06145217
- **Lead sponsor:** Xspray Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-22
- **Primary completion:** 2023-08-22
- **Final completion:** 2023-08-29
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06145217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06145217, "An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL®". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06145217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*